Correlation between the presence of the nuclear AR-V7 androgen receptor and clinical evolution of prostate cancer: in vitro analysis of a combination of compounds targeting PI3K by Cattarino, Susanna
	 1	
	
	
	
		 		 	Facoltà	di	Medicina	e	Odontoiatria	Dipartimento	di	Medicina	Interna	e	specialità	mediche	Direttore:	Prof.	S.	Filetti	
		 Tesi	di	Dottorato	in		
TECNOLOGIE	BIOMEDICHE	IN	MEDICINA	CLINICA	
	
Correlation	between	the	presence	of	the	nuclear	AR-V7	androgen	
receptor	and	clinical	evolution	of	prostate	cancer:	in	vitro	analysis	of	a	
combination	of	compounds	targeting	PI3K	
	
	
	Relatore:		 	 	 	 																				Candidato:	Prof.	A.	Sciarra																																													Susanna	Cattarino																																																																										Matricola:	942461	Correlatore:	Dr.	F.	Blefari	
	
Anno	Accademico	2017/2018	
	
	 2	
INDEX	
	1. Introduction																																																																																													Page			3				1.1 Role	of	androgen	receptors	in	the	PCa	progression													Page			4	1.2 Ar-dependent	mechanisms	in	the	progression	of	PCa									Page	5	-AR	amplification	-Point	mutations	-Androgens	intracrine	biosynthesis	-Splicing	variants	-Non-canonical	transactivation	of	AR								1.3		Pi3K/AKT/mTOR																																																																												Page	8															-pTEN															-AKT															-mTOR	2.	Material	and	Methods																																																																													Page	13							2.1	Ex-vivo	AR-V7	expression																																																													Page	13							2.2	In-vitro	analysis																																																																																Page	15															-Cell	lines															-Cell	viability	assay															-	Cell	proliferation	assay															-Western	blot														-	Flow	cytometry	analysis					2.3	Statistical	analysis																																																																															Page	21				3.	Results																																																																																																								Page	21									3.1	Ex-vivo	AR-V7	expression									3.2	In-vitro	analysis				4.	Discussion																																																																																																	Page	26																																																																																																													5.	References																																																																																																		Pag.	28	
	 3	
Correlation	 between	 the	 presence	 of	 the	 nuclear	 AR-V7	 androgen	 receptor	 and	
clinical	 evolution	 of	 prostate	 cancer:	 in	 vitro	 analysis	 of	 a	 combination	 of	
compounds	targeting	PI3K	
	INTRODUCTION	
PROSTATE	CANCER	Prostate	cancer	 (PCa)	 is	 the	second	most	 frequently	diagnosed	cancer	 in	men.	According	 to	the	National	Cancer	Institute,	there	are	about	137.9	new	cases	per	100,000	men	per	year.	PCa	is	 the	 second	 leading	 cause	 of	 cancer-related	 mortality	 among	 men	 and	 the	 third	 leading	cause	of	cancer	death.	An	increase	in	the	PCa	incidence	associated	with	an	aging	population	is	also	expected	(1).		PCa	 is	 a	 multiform	 and	 biologically	 very	 heterogeneous	 disease;	 some	 patients	 have	 an	indolent	 disease	 with	 few	 symptoms	 while	 others	 have	 a	 highly	 aggressive	 disease	 and	progresses	 into	 metastatic	 carcinoma	 refractory	 both	 to	 hormone	 therapy	 and	 to	chemotherapy.		Patients	 with	 localized	 PCa	 are	 successfully	 treated	 with	 radical	 prostatectomy	 (RP)	 or	radiotherapy	 (RT).	Despite	 the	high	 rates	of	 progression-free	 survival	 (PFS),	 approximately	30%	of	patients	treated	with	surgery	and	30-50%	of	those	treated	with	RT	have	recurrence	of	the	disease,	demonstrated	by	the	rise	in	PSA	values.	Clinical	relapse	involves	a	variable	time	that	can	go	from	1-8	years,	on	average	5.	The	PSA	increase	does	not	define	a	local	recurrence	from	 a	 distant	 micrometastasis.	 High	 Gleason	 scores	 are	 associated	 with	 a	 greater	 risk	 of	recurrence	(2).		Patients	with	 the	metastatic	 PCa	 are	 treated	with	 hormone	 therapy	 (androgen	 deprivation	therapy,	ADT).	Despite	the	initial	high	response	rate	to	ADT,	most	patients	develop	resistance	to	 ADT.	 The	 progression	 time	 towards	 the	 metastatic	 form	 of	 the	 disease,	 known	 as	castration-resistant	prostate	cancer	(CRPC),	is	different	for	each	patient,	often	within	the	first	year	of	metastatic	disease.	CRPC	 is	 defined	when	 serum	 testosterone	 is	 <50	 ng	 /	 dL	 and	 at	 least	 one	 or	more	 of	 the	following	criteria	are	present:	1)	 increase	 in	serum	 levels	of	specific	prostate	antigen	(PSA)	(biochemical	 progression),	 2)	 development	 of	 symptoms	 in	 the	 presence	 of	 pre-existing	cancer	 (clinical	 progression)	 or	 3)	 identification	 of	 new	 metastatic	 lesions	 at	 imaging	(radiographic	 progression).	 For	 this	 group	 of	 patients	 in	 addition	 to	 traditional	 treatment	based	 on	 taxanes,	 docetaxel	 and	 recently,	 cabazitaxel	 (3),	 treatment	 with	 abiraterone	 and	
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enzalutamide,	which	 target	 the	 androgen	 receptor	 axis	 (4,5),	 has	 been	 approved.	However,	some	 patients	 have	 shown	 primary	 resistance	 to	 these	 agents	 but	 the	 mechanisms	 of	resistance	are	not	yet	fully	understood	(6).	The	 key	 mechanisms	 in	 the	 progression	 of	 androgen-dependent	 disease	 to	 CRCP	 can	 be	attributed	 to	 several	 potential	 molecular	 mechanisms,	 such	 as:	 increase	 in	 androgen	biosynthesis	in	the	tumor	microenvironment	or	use	of	adrenal	androgens	and	cholesterol	as	androgen	precursors;	somatic	changes	of	AR	resulting	in	an	increased	affinity	for	the	ligand;	amplifications	of	the	AR	gene;	splicing	variants	of	constitutively	active	AR	and	non-canonical	activations	of	AR	(7,8).	Recently,	 an	 interaction	 between	 AR	 and	 PI3K/AKT/mTOR	 has	 been	 highlighted	 (9-11).	Inactivation	of	AR	leads	to	over-regulation	of	PI3K	(12-14).	PI3K/AKT/mTOR	is	important	for	proliferation	and	survival	of	normal	cells	and	is	regulated	by	the	oncosuppressor	Phosphatase	and	tensin	homolog	(PTEN).	The	lack	of	PTEN	activity	leads	to	a	continuous	activation	of	the	PI3K	pathway	 that	has	been	correlated	 to	an	altered	control	of	cell	growth	and	survival,	an	increased	metastatic	competence,	angiogenesis	and	resistance	to	chemotherapy	(15,16).	The	loss	 of	 the	 PTEN	 oncosuppressor	 and	 the	 consequent	 uncontrolled	 activation	 of	 the	 PI3K	signaling	 pathway	was	 found	 in	 40%	 of	 the	 primary	 tumors	 and	 in	 70%	 of	 the	metastatic	forms	of	PCa	(17).		Furthermore,	 the	 inflammatory	 cytokines	 (CCR9,	 IL-6,	 and	 TLR3)	 regulate	 the	 PI3K/AKT	signal	in	the	apoptotic	mechanisms	of	PCa	cells.	IL-6	is	over-expressed	in	some	PCa	and	may	induce	resistance	to	hormone	therapy	(18).		
ROLE	OF	ANDROGEN	RECEPTORS	IN	THE	PCA	PROGRESSION	The	 androgen	 receptor	 (AR)	 gene	 is	 located	 on	 the	X	 chromosome	 (Xq11-12)	 and	 contains	eight	exons	that	encode	a	110	kDa	protein	(Figure	1).	The	AR	protein	consists	of	a	domain	of	trans-activation	of	the	terminal	NH2	(NTD,	encoded	by	exon	1),	a	DNA-binding	domain	(DBD,	coded	by	 exons	 2	 and	3),	 a	 region	 of	 hinge	 (H,	 encoded	by	 the	 portion	5	 of	 exon	4)	which	contains	 the	 nuclear	 localization	 signal	 (NLS)	 and	 a	 ligand-binding	 domain	 (LBD	 /	 CTD,	encoded	by	the	remaining	exon	4	through	exon	8).(19,20)	Testosterone	and	dihydrotestosterone	(DHT)	bind	to	 the	LBD	of	AR	and	 induce	a	change	 in	the	conformation	of	the	protein	leading	to	detachment	from	chaperonins	and	exposes	the	NLS	in	the	region	of	the	hinge.	The	AR	dimerizes	and	translocates	to	the	nucleus	where	it	interacts	with	 transcriptional	 co-regulators,	 binds	 to	 the	 androgen	 response	 elements	 (ARE)	 and	regulates	the	transcriptional	output	of	the	many	genes	regulated	by	androgens	according	to	
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the	 cell	 type.	 In	 prostate	 epithelial	 cells,	 AR	 regulates	 the	 expression	 of	 the	 transcription	factors	of	the	NKX3.1	and	FOX	family,	IGF1R,	UBE2C,	UGT2B15,	KLK3,	TMPRSS2,	FKBP5	and	other	genes	that	control	cell	growth,	differentiation	and	function	both	in	the	normal	prostate	and	during	the	growth	and	progression	of	PCa.	
	Figure	1:	The	Androgen	receptor		
AR-DEPENDENT	MECHANISMS	IN	THE	PROGRESSION	OF	PCA	The	 role	 of	 AR-induced	 signals	 in	 the	 PCa	 initiation	 phase	 is	 not	 yet	 fully	 understood.	 AR	generally	 does	 not	 exhibit	 alterations	 in	 the	 primary	 tumor,	 however	 about	 50%	 of	 the	localized	disease	may	present	alterations	in	the	regulation	of	AR.	The	continuous	activation	of	the	AR	signal,	on	the	other	hand,	plays	an	essential	role	in	the	development	of	the	CRPC	(21).	An	 increased	expression	of	AR	 is	 constantly	observed	 in	 tumor	epithelial	 cells	during	CRPC	development,	 while	 a	 loss	 in	 the	 AR	 signal	 pathway	 is	 generally	 observed	 in	 the	 primary	tumor	and	in	the	metastasis	stroma.	So	far,	numerous	genetic	mutations	have	been	identified	in	the	AR	locus	involved	in	the	mechanisms	leading	to	CRPC,	such	as:	amplifications	of	the	AR	gene,	mutations	in	the	receptor-hormone	binding	domain;	expression	of	splicing	variants.	All	of	 these	conditions	can	promote	a	continuous	AR	signal	even	 in	 the	condition	of	 low	serum	testosterone	levels	(22).	-AR	AMPLIFICATION	The	 amplification	 of	 AR	 is	 the	most	 frequent	 genetic	 alteration	 reported	 for	 CRPC	 tumors,	observed	in	more	than	50%	of	cases,	while	it	is	detected	by	in	situ	hybridization	(FISH),	only	rarely	 in	 untreated	 primary	 tumors,	 suggesting	 that	 the	 AR	 amplification	 is	 an	 adaptive	response	to	the	ADT(23-25).	AR	over-expression	in	tumor	epithelial	cells	may	be	the	result	of	AR	gene	amplification,	but	is	probably	also	an	instant	castration	response	because	androgens	normally	suppress	AR	transcription	in	prostate	epithelial	cells.	 Increased	AR	expression	can	sensitize	the	cells	of	the	PCa	to	sub-physiological	levels	of	androgen	and	has	been	associated	with	therapeutic	resistance	to	both	the	enzyme	inhibitor	(AR	antagonist)	and	the	abiraterone	
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acetate	 (26-29).	 The	 cells	 that	 over-express	 AR	 are	 able	 to	 access	 a	 greater	 number	 of	chromatin	binding	sites,	generating	an	altered	AR	transcriptome.	-POINT	MUTATIONS	Point	mutations	of	AR	can	also	continually	activate	the	AR-induced	signal	in	tumor	epithelial	cells.	These	mutations	are	very	rare	 in	untreated	PCa,	but	have	been	reported	in	15-20%	of	CRPC	patients	and	up	to	40%	of	CRPC	patients	treated	with	AR	antagonists,	suggesting	that	they	may	occur	selectively	 in	response	 to	ADT	(9,	16,	30,	31).	Several	point	mutations	with	function	gain	were	characterized,	predominantly	in	the	c-terminal	region	of	LBD,	while	about	one-third	occur	 in	NTD,	 resulting	 in	 increased	 specificity	 for	 adrenal	 androgenes	 and	other	steroid	 hormones,	 (including	 DHEA,	 progesterone	 ,	 estrogen	 and	 glucocorticoids)	 and	activation	of	the	AR	androgens	or	enlarge	the	specificity	of	the	ligand	(32).	Two	well-known	examples	are	AR-T877A	and	AR-W741C,	originally	described	in	LNCaP	cells,	which	 convert	 the	 antiandrogens	 flutamide	 and	 bicalutamide	 into	 partial	 agonists,	respectively	(33-35).	-ANDROGENS	INTRACRINE	BIOSYNTHESIS	An	alternative	mechanism	to	activate	 the	AR	signal	 is	 through	the	conversion	of	cholesterol	and	adrenal	androgen	precursors	into	testosterone	and	DHT	in	PCa	cells	even	in	the	absence	of	circulating	androgens	produced	by	the	testes	(36).	The	 enzymes	 responsible	 for	 the	 conversion	 of	 cholesterol	 into	 androgens	 precursors	(CYP17A1,	HSDD3B2)	and	the	conversion	of	androgens	precursors	into	testosterone	and	DHT	(AKR1C3,	SRD5A1	/	2)	are	increased	about	8-10	times	in	CRPC	(37,38).	It	is	believed	that	the	over-regulation	 of	 genes	 involved	 in	 androgen	 production	 can	 increase	 androgen	concentrations,	further	facilitating	the	reactivation	of	the	AR	signaling	pathway	(30).	Several	mutations	have	been	demonstrated	that	correlate	with	the	development	of	resistance	to	abiraterone,	for	example	high	levels	of	CYP17A1	and	mutations	with	gain	in	function	may	sensitize	AR	 to	 non-androgenic	 ligands.	 This	 demonstrates	 a	 possible	mechanism	by	which	the	same	enzymatic	process	of	synthesis	of	steroid	hormones	could	be	altered	at	the	genomic	level	to	guide	the	development	of	resistance	to	ADT	therapy	(37).	-SPLICING	VARIANTS		In	recent	years	splice	variants	(AR-V)	have	been	studied	to	highlight	their	contribution	to	the	development	 of	 CRPC	 (39-44).	 A	 constitutively	 active	 AR	 may	 result	 from	 splicing	 or	alternative	gene	rearrangement	of	the	AR	gene.	The	expression	of	AR-V	is	well	documented	in	the	PCa	 cell	 lines,	 in	 the	xenograft	 tumors	as	well	 as	 in	 the	 clinical	 samples	of	PCa	 (42,43).	Most	AR-V	results	from	a	truncated	AR	in	the	terminal	C	region,	leading	to	loss	of	LBD.	In	AR-
	 7	
Vs,	 mutations	 in	 exons	 3	 and	 4	 result	 in	 changes	 in	 NLS	 and	 an	 AR	 with	 predominantly	cytoplasmic	localization.	However,	other	AR-Vs	contain	both	exons	3	and	4	and	are	therefore	able	to	translocate	into	the	nucleus	and	activate	AR	target	genes	independently	of	the	ligand	(45).	AR-V7,	the	splicing	variant	best	characterized	to	date,	is	constitutively	active	despite	lacking	a	complete	NLS,	through	a	mechanism	that	has	not	yet	been	completely	determined.	 Just	as	 it	has	 not	 yet	 been	 completely	 clarified	 whether	 the	 profile	 of	 the	 genes	 activated	 for	 this	variant	 is	 the	 same	 as	 for	 full-length	 ARs.	 The	 presence	 of	 AR-V	 variants	 has	 substantial	implications	 for	 the	 treatment	 of	 CRPC	 (46).	 AR-V	 are	 generally	 over-expressed	 in	 bone	metastases	and	correlate	with	a	reduced	survival	rate	after	surgery	(46,47).	In	particular,	the	presence	 of	 AR-V7	 in	 tumor	 cells	 circulating	 from	 patients	 treated	 with	 enzalutamide	 or	abiraterone	was	associated	with	therapeutic	resistance	to	both	agents	(48).	Patients	with	AR-V7-positive	 treated	 with	 enzalutamide	 or	 abiraterone	 showed	 lower	 PSA	 response	 rates,	shorter	 free	 progression-free	 survival,	 shorter	 progression-free	 clinical	 or	 radiographic	survival,	and	shorter	overall	survival	compared	to	patients	with	AR-V7-negative	(48).	A	new	therapeutic	strategy	able	to	inhibit	both	the	AR	is	addressed	and	towards	the	terminal	N	region	of	RA,	which	is	conserved	in	all	AR	isoforms.	A	particular	 interest	has	elicited	EPI-001,	 a	 small	 antagonist	molecule	derived	 from	bisphenol	A,	which	covalently	binds	 the	AR-terminal	domain	and	has	shown	to	block	the	transcriptional	activity	of	AR	and	different	AR-Vs,	including	AR-V7	(49).	-NON-CANONICAL	TRANSACTIVATION	OF	AR		Numerous	growth	factors,	cytokines	and	hormones	have	been	implicated	in	the	activation	of	AR	 in	 the	 absence	 of	 androgens	 or	 present	 at	 sub-physiological	 concentrations.	 The	 non-canonical	 induction	 of	 the	 AR	 signaling	 pathway	 has	 been	 related	 to	 mechanisms	 that	promote	phosphorylation	of	AR	itself	(50).	 In	particular,	 it	has	been	shown	that	the	 insulin-like	 growth	 factor-1	 (IGF-1)	 is	 able	 to	 induce	 the	 AR	 transcriptional	 activity	 in	 androgen	deprivation	 conditions	 in	 vitro,	 an	 effect	 that	 could	 be	 inhibited	 by	 bicalutamide	 (51)	 .	Furthermore,	it	has	been	seen	that	the	activation	of	ARF	mediated	by	IGF-1	also	requires	the	expression	of	integrin	β	(1A),	as	it	facilitates	the	functional	interaction	between	the	activated	IGF-1	 receptor	 and	 AR,	 leading	 subsequently	 to	 independent	 growth	 from	 PCa	 anchorage	(52).	Interleukin-6	(IL-6)	also	activates	AR	genes	and	increases	PSA	secretion	in	cell	cultures.	In	 particular,	 in	 the	 absence	 of	 androgens,	 it	 has	 been	 shown	 that	 IL-6	 induces	 (probably	through	 Stat3	 signal	 transducer	 and	 activator	 of	 transcription,	 signal	 transducers	 and	transcription	activators)	an	increased	expression	of	genes	regulated	by	AR	(53).	
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PI3K	/	AKT	/	mTOR	The	PI3K-AKT-mTOR	signaling	pathway	is	an	ancient	signal	transduction	pathway,	preserved	by	 worms	 to	 humans,	 which	 has	 evolved	 as	 an	 essential	 regulator	 of	 the	 catabolic	 and	anabolic	processes	of	the	cell.	It	is	often	related	to	numerous	cancers	including	PCa.	It	plays	a	critical	role	in	linking	nutrient	and	growth	factor	perception	with	numerous	cellular	processes,	 such	 as	 protein	 synthesis,	 proliferation,	 survival,	metabolism	 and	 differentiation	(54).	 The	 different	 signal	 pathways	 are	 mediated	 by	 numerous	 effectors	 that	 modulate	phosphorylation,	transcription	and	translation.	The	activation	of	 the	PI3K	kinase	 is	a	central	mechanism	between	upstream	growth	signals	and	downstream	signal	transduction	mechanisms.	PI3Ks	are	grouped	into	three	classes	(I-III)	based	 on	 their	 substrate	 preference	 and	 sequence	 homology.	 Their	 primary	 function	 is	 to	phosphorylate	 the	 3'-hydroxyl	 group	 of	 phosphatidylinositol	 and	 phosphoinositides.	 Most	relevant	 in	 tumors	 is	 the	 class	 IA	PI3K,	which	 includes	 two	 functional	 subunits	 that	 form	a	heterodimer:	 a	 catalytic	 subunit	 (p110α,	 p110β	or	 p110δ)	 and	 a	 regulatory	 subunit	 (p85α,	p55α,	p50α,	p85Î²	or	p85Î³).	A	series	of	signals	stimulate	the	activity	of	PI3K,	mainly	through	tyrosine	kinase	receptors	(RTK),	but	also	through	receptors	coupled	to	G	proteins	(GPGR)	and	oncogenes	such	as	Ras	that	directly	bind	p110.	After	stimulation,	the	catalytic	subunit	of	PI3K	phosphorylates	 phosphatidylinositol-4,5-bisphosphate	 (PI-4,5-P2)	 to	 phosphatidylinositol-3,4,5-triphosphate	 (PI-3,4,5-P3),	 which	 acts	 as	 a	 second	 messenger	 to	 recruit	 a	 series	 of	proteins	containing	homology	domain	with	the	cell	membrane	pleckstrin.	The	 kinases	 belonging	 to	 class	 IA	 are	 constituted	 by	 a	 catalytic	 subunit	 and	 a	 regulatory	subunit.	The	catalytic	subunits	p110α,	p110β	or	p110δ	are	encoded	by	the	PIK3CA,	PIK3CB	and	PIK3CD	genes,	respectively.	The	regulatory	subunits	are	instead	p85α	(in	the	p85α,	p55α,	p50α,	p85β	and	p55Î	±	isoforms,	encoded	by	the	PIK3R1,	PIK3R2	and	PIK3R3	genes.	The	IB	class	consists	of	a	single	catalytic	subunit,	P110γ,	and	two	regulatory	subunits,	p84	and	p101.	Class	 II	 PI3Ks	 are	monomeric	 proteins	 that	 include	 three	 isoforms:	 PI3KC2α,	 PI3KC2β	 and	PI3KC2γ.	Class	III	is	more	structurally	similar	to	class	I	and	exists	as	a	heterodimer	composed	of	 a	 catalytic	 subunit	 (Vps34)	 and	 a	 regulatory	 subunit	 (p150).	 Class	 IA	 PI3K	 kinases	 are	activated	by	stimulation	of	growth	factors	through	tyrosine	kinase	receptors	(RTK).	The	p85	regulatory	subunit	 is	directly	bound	to	 the	phosphotyrosine	residues	of	RTK	receptors;	 this	binding	 abolishes	 the	 intramolecular	 inhibition	 of	 the	 p110	 catalytic	 subunit	 by	 p85	 and	localizes	PI3K	in	the	plasma	membrane,	where	its	PIP3	substrate	resides	(55,56).	
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An	uncontrolled	PI3K	signal	is	very	common	in	cancer.	Mutations	in	the	tumor	cells	from	the	colon,	 lung,	 prostate,	 liver	 and	 brain	 revealed	 mutations	 in	 the	 PI3KA	 gene	 that	 encodes	p110α.	This	gene,	in	addition	to	being	involved	in	the	processes	of	regulation	of	the	cycle	and	of	 cell	 growth,	 acquires	 a	 very	 important	 role	 in	 endothelial	 cells,	 promoting	 angiogenesis	and,	 therefore,	 the	 formation	 of	 a	 vascular	 network	 essential	 for	 the	 contribution	 of	substances	nutritive	and	oxygen,	and	which	can	ultimately	guarantee	a	pathway	of	metastasis	from	the	primary	lesion	(57).	-PTEN	PTEN	(Phosphatase	and	tensin	homolog)	 is	a	key	molecule	 in	 the	regulation	of	PI3K	/	AKT.	The	 PTEN	 function	 as	 tumor	 suppressor	 is	 performed	 through	 the	 phosphatase	 activity,	dephosphoryl	PIP3	to	PIP2,	which	negatively	regulate	the	activation	of	the	PI3K	/	PDK1	/	AKT	pathway	 (58,59).	 This	 phosphatase	 can	 act	 on	 both	 lipids	 and	 proteins,	 and	 acts	 as	 tumor	suppressor,	inhibiting	cell	proliferation	and	inducing	apoptosis,	especially	in	cells	that	present	the	so-called	anikis.	Mutations	in	PTEN	inhibit	the	oncosuppressor	activity,	in	particular	two	main	mutations	in	the	phosphatase	domain:	one	involves	the	loss	of	phosphatase	activity	both	on	 lipids	 and	 on	 proteins	 while	 the	 other	 only	 affects	 phosphatase	 activity	 on	 protein	substrates	.	In	addition	to	regulating	the	PI3K	/	AKT	signal	pathway,	PTEN	has	many	other	critical	roles	in	tumors,	including:	genomic	instability,	tumor	cell	renewal,	cellular	senescence,	cell	migration	and	 metastasis.	 Finally,	 PTEN	 plays	 a	 significant	 role	 in	 the	 regulation	 of	 tumor	microenvironment	(58).	Mutations	in	PTEN	on	germ	cells	result	in	a	rare	hereditary	disease,	Cowden's	disease,	which	is	associated	with	a	higher	risk	of	neoplastic	diseases.	Mutations	in	the	PTEN	gene	have	been	observed	 in	cancer	of	 the	breast,	prostate,	endometrium,	ovaries,	colon,	melanoma,	 glioblastoma	 and	 lymphoma.	 Studies	 on	 animal	models	 have	 also	 shown	that	the	loss	of	a	single	copy	of	the	PTEN	gene	is	sufficient	to	interrupt	the	cellular	signal	and	initiate	an	uncontrolled	growth	of	the	cell.	
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					Figure	2.	The	PI3K/AKT/mTOR	pathway		-AKT	AKT,	 or	 protein	 kinase	 B	 (PKB),	 is	 a	 serine	 /	 threonine	 kinase	 of	 the	AGC	 kinase	 family.	 It	exists	 in	 3	 structurally	 similar	 isoforms:	 PKBα,	 PKBβ	 and	 PKBγ.	 The	 three	 isoforms	 are	composed	 of	 characteristic	 domains.	 The	 Pleckstrin	 Homology	 (PH)	 domain	 has	 a	 notably	conserved	 tertiary	 structure	 despite	 the	 aminoacid	 sequence	 presenting	 differences;	 this	domain	 is	 responsible	 for	 the	 link	 with	 PIP3.	 The	 LIN	 domain,	 the	 hinge	 region	 of	 39	aminoacids,	 is	 the	 region	 that	 connects	 the	PH	domain	with	 the	 catalytic	 domain,	 is	 poorly	conserved	among	the	AKT	isoforms	(17-46%	identical)	and	has	no	significant	homology	with	any	other	human	protein	(60).	The	kinase	domain,	extending	from	amino	acids	148-411	and	ending	in	a	regulating	hydrophobic	motif	(CTD),	is	the	portion	of	the	enzyme	that	binds	ATP;	the	ATP-binding	site	of	25	residues	has	a	homology	of	96-100%	in	the	three	isoforms.	The	C-terminal	 hydrophobic	 domain	 is	 conserved	 in	 the	 AGC	 kinase	 family.	 These	 hydrophobic	residues	play	a	critical	role	in	the	complete	activation	of	AKT	for	substrate	phosphorylation.	Inside	there	is	another	key	residue	for	the	activation	of	the	enzyme,	Ser473.	
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While	AKT1	is	expressed	ubiquitely	at	high	levels	with	exception	of	kidney,	liver	and	spleen,	AKT2	expression	is	elevated	at	the	level	of	insulin-sensitive	tissues	such	as	brown	fat,	skeletal	muscle	 and	 liver.	 The	 expression	 of	 AKT3	 is	 ubiquitous,	 although	 low	 levels	 of	 expression	have	been	found	in	the	liver	and	in	skeletal	muscle.	These	different	isoforms	are	implicated	in	specific	 functions.	For	example,	 the	amplification	and	over-expression	of	AKT2	 is	 related	 to	increased	motility	and	cell	 invasion,	while	 increased	AKT3	activity	appears	 to	contribute	 to	the	 aggressiveness	 of	 steroid-induced	 tumors.	 All	 three	 isoforms	 are	 activated	 through	phosphorylation:	the	first	occurs	on	a	threonine	residue	while	the	second	occurs	on	a	serine	residue	in	the	hydrophobic	motif.	Once	activated,	AKT	recognizes	and	phosphorylates	serine	or	threonine	residues	of	numerous	substrates,	 such	 as:	 tuberosis	 sclerosis	 complex	 (TSC)	2,	 glycogen	 synthase	 kinase	 (GSK)	3,	forkhead	 box	 transcription	 factors	 (FoxO),	 p21WAF1	 /	 CIP1,	 p27KIP1,	 caspase	 -9	 and	BAD	(Bcl-2	 associated	 death	 promoter)	 and	 iNOS,	 which	 regulate	 numerous	 processes	 that	coordinate	the	life	and	death	of	the	cell,	metabolism	and	angiogenesis	(61).	The	hyperactivation	of	AKT	has	been	shown	in	numerous	cancers,	such	as:	multiple	myeloma,	lung	cancer,	glioblastoma,	breast	cancer	and	also	prostate	cancer	(61).	The	 best	 studied	 downstream	 substrate	 of	 AKT	 is	 the	mTOR	 kinase	 (62).	 AKT	 can	 directly	phosphorylate	 and	 activate	 mTOR,	 as	 well	 as	 may	 cause	 indirect	 activation	 of	 mTOR	 by	phosphorylating	 and	 inactivating	 TSC2	 (tuberous	 sclerosis	 2,	 also	 called	 tuber),	 which	normally	 inhibits	mTOR.	The	consequence	of	mTOR	activation	is	an	increased	translation	of	proteins.	Finally,	 it	has	 recently	been	shown	 that	AKT	activity	 can	be	negatively	 regulated	by	 the	PH	domain	 of	 phosphatase	 rich	 in	 repeated	 sequences	 of	 leucine	 (PHLPP)	 which	 specifically	dephosphoryates	the	hydrophobic	motif	of	AKT	(Ser473	in	Akt1).	-mTOR	mTOR	(mammalian	target	of	rapamycin)	is	a	serine	/	threonine	kinase	that	regulates	growth,	proliferation,	motility	and	cell	survival,	transcription	and	protein	synthesis	(62).	mTOR	plays	an	 important	 role	 in	 regulating	 the	 body's	 energy	 balance	 and	 its	 weight;	 is	 activated	 by	amino	acids,	 glucose,	 insulin	and	other	hormones	 involved	 in	 the	 regulation	of	metabolism.	Recent	 studies	 have	 shown	 that	 mTOR	 is	 not	 only	 a	 substrate	 of	 AKT,	 but	 also	 a	 crucial	activator:	 mTOR	 in	 fact	 forms	 a	 complex	 with	 the	 RICTOR	 protein	 (Rapamycin-insensitive	companion	of	mTOR)	 and	 then	directly	phosphorylate	 Ser473	of	Akt.	The	 activation	of	 this	complex	(TORC2)	could	explain	the	sequestration	of	the	mTOR	molecules	just	formed	inside	the	 cells	 during	 long-term	 treatments	 with	 rapamycin.	 This	 drug	 is	 in	 fact	 particularly	
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effective	in	inducing	apoptosis	and	in	suppressing	the	proliferation	of	cells	that	over-express	Akt	as,	over	time,	it	interferes	with	the	reassembly	of	the	complex	by	joining	it	(63).	Given	the	critical	role	of	PI3K-AKT-mTOR	in	normal	cell	physiology,	 it	 is	not	surprising	that	the	pathway	is	deregulated	in	a	wide	range	of	tumors,	genetic	alterations	have	been	identified	as	loading	all	components	of	this	signal	pathway.		In	PCa,	 the	PI3K-AKT-mTOR	pathway	 is	deregulated	 in	42%	of	 the	 localized	disease	and	 in	100%	 of	 the	 advanced	 disease,	 indicating	 that	 the	 alterations	 in	 these	 signals	 may	 be	 an	essential	 prerequisite	 for	 the	 development	 of	 CRPC	 (64-67).	 The	 functional	 importance	 of	mutations,	 gene	 amplifications	 and	 changes	 in	 mRNA	 expression	 in	 PI3K	 pathway	components	 is	highlighted	by	 the	significant	 correlation	with	 the	prognosis	of	PCa	patients.	For	example,	a	reduced	expression	of	PTEN,	is	associated	with	a	higher	Gleason,	biochemical	recurrences	 after	 prostatectomy,	 and	 shorter	 times	 to	 metastasis	 (67).	 Furthermore,	 high	levels	 of	 phospho-4EBP1	 and	 eI4E	 are	 associated	with	 an	 increase	 in	mortality	 of	 patients	with	PCa,	indicating	that	even	the	downstream	effectors	of	the	route	are	predictive	of	disease	progression	(68).	Results	from	studies	on	knockout	and	transgenic	mouse	models	also	clearly	showed	the	role	of	 PI3K-AKT-mTOR	 in	 PCa	 development.	 In	 particular,	 the	 over-expression	 of	 AKT	 or	 the	biallelic	loss	of	the	PTEN-suppressor	in	prostate	epithelial	cells	leads	to	hyperactivation	of	the	route	and	is	sufficient	for	the	development	of	in	vivo	PCa	(69-71).	Conditional	KT	of	mTOR	in	a	mouse	PCa	model	caused	by	PTEN	deletion	inhibits	prostate	tumorigenesis,	demonstrating	the	need	for	an	intact	signaling	axis	to	guide	cell	transformation	in	prostate	epithelial	cells.	It	is	interesting	to	note	that	others	have	shown	that	the	simultaneous	loss	of	PTEN	and	RICTOR,	a	 component	 that	 defines	 the	mTORC2	 complex,	 reduces	 the	 incidence	 of	 PCa	 formation	 in	mice.	 Thus,	 the	 hyperactivation	 of	 PI3K-AKT-mTOR	 is	 sufficient	 to	 induce	 the	 formation	 of	PCa,	 and	 both	 mTORC1	 and	 mTORC2	 are	 necessary	 to	 facilitate	 this	 in	 vivo	 process.	 In	particular,	overexpression	of	the	oncogenic	AKT	or	the	biallelic	loss	of	the	tumor	suppressor	PTEN	 in	 the	 epithelial	 cells	 of	 the	 prostate	 leads	 to	 the	 hyperactivation	 of	 the	 route	 and	 is	sufficient	for	the	development	of	in	vivo	PCa.	Conditional	KO	of	mTOR	in	a	murine	PCa	model	caused	 by	 PTEN	 deletion	 inhibits	 prostate	 tumorigenesis,	 demonstrating	 the	 need	 for	 an	intact	signaling	axis	to	guide	cell	transformation	in	prostate	epithelial	cells.	It	is	interesting	to	note	 that	others	have	shown	that	 the	simultaneous	 loss	of	PTEN	and	RICTOR,	a	component	that	defines	the	mTORC2	complex,	reduces	the	incidence	of	PCa	formation	in	mice	(72,73).	The	aim	of	 this	work	was	 to	evaluate	 the	presence	of	 the	AR-V7	splicing	variant	 in	patients	with	PCa.	The	data	obtained	from	biopsies	of	patients	affected	by	PCa	were	then	correlated	to	
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the	Gleason	Score	and	to	the	evolution	of	the	disease.	Furthermore,	in	vitro,	we	have	analyzed	the	effects	of	a	combination	of	compounds	that	target	the	signaling	pathway	of	AR	and	PI3K	/	AKT	/	mTOR.		MATHERIAL	AND	METHODS	Our	experimental	activity	was	composed	by	two	different	levels:	1. Receptor	 mutations	 with	 particular	 attention	 to	 the	 expression	 of	 AR-V7	 were	evaluated	on	samples	derived	 from	radical	prostatectomies	of	70	patients	diagnosed	with	 prostate	 adenocarcinoma,	 subdivided	 according	 to	 the	 risk	 class	 (D’Amico	classification)	 and	 the	 neoplastic	 progression	 (EAU	 definition	 of	 neoplastic	progression).		2. At	the	same	time	we	evaluated	the	effects	of	some	therapies	compounds	on	cell	 lines	that	have	a	different	set-up	of	AR,	LnCaP	and	VCaP.		1.	EX	VIVO	AR-V7	EXPRESSION	This	experimental	study	was	conducted	after	approval	of	the	protocol	from	our	Institutional	Board	Committee	and	informed	consent	was	obtained	from	all	patients.	Exclusion	criteria	for	the	 study	 were:	 previous	 hormonal,	 surgical	 or	 radiation	 therapies	 for	 prostate	 diseases;	acute	 inflammatory	 diseases.	 Inclusione	 criteria	 are:	 Hystological	 diagnosis	 of	 prostate	adenocarcinoma	 at	 prostate	 biopsy,	 no	 pregressive	 treatments	 (radiotherapy,	 ormonal	therapy)	for	PCa,	possibility	to	give	an	informed	consent.	Table	1	summarizes	the	caharacteristics	of	donors.	All	sections	derived	from	70	patients	undergoing	radical	prostatectomy	PCa.	For	each	patient	we	collected	5	mm	sections	from	paraffin-embedded	PCa	tissues.	The	histological	status	of	the	tissue	(pathological	stage,		Gleason	Score,	surgical	margins)	was	checked	by	an	independent	pathologist.	We	 devided	 patients	 into	 three	 groups	 according	 to	D’Amico	 risk	 stratification	system:	Low-risk	Group	was	defined	as	T1/T2a,	and	PSA	≤10	ng/	ml,	and	Gleason	score	≤6.	Intermediate-risk	 Group	 was	 defined	 as	 T2b,	 and/or	 PSA	 10–20	 ng/mL	 and/or	 Gleason	 7	disease.	High-risk	Group	was	classified	as	having	any	one	of	the	following	high-risk	features:	≥T2c,	PSA	>20	ng/mL	or	Gleason	8–10	disease.	 In	each	group	we	divided	patients	 into	 two	subgroups:	Presence	or	absence	of	neoplast	progression.	Neoplastic	progression	is	defined	as:	increase	 in	 serum	 levels	 of	 specific	 prostate	 antigen	 (PSA)	 (biochemical	 progression),	 2)	development	of	symptoms	in	the	presence	of	pre-existing	cancer	(clinical	progression)	or	3)	identification	of	new	metastatic	lesions	at	imaging	(radiographic	progression).		
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	Number	of	cases	 72	Prostate	Volume	(ml)	 78.39	±	6.8	Age	(years)	 64.76	±	3.3		PSA	(ng/mL)	 15.8	±2.4	Low	risk	group	-Progression	-No	Progression	
14	(19.4%)	0	14	Intermediate	 risk	group	-Progression	-No	Progression	
14	(19.4%)		0	14	High	risk	group	-Progression	-	No	progression	
44	(61.1%)	22	22		Table	1:	Characteristics	of	population		The	expression	of	anti	AR-V7	was	evaluated	by	immunoperoxidase	staining	on	5	mm	sections	from	 paraffin-embedded	 human	 PCa	 tissues	 using	 a	 streptavidin-biotin-peroxidase	 system	(UCS	Diagnostic),	according	to	the	manufacturer’s	instructions.	Sections	were	de-paraffinized	and	endogenous	peroxidase	was	blocked	with	3%	hydrogen	peroxide	in	PBS	for	10	min.	For	antigen	 retrieval	 the	 sections	 were	 incubated	 in	 buffer	 pH	 9.0	 (5%	 Tris,	 1.5%	 2-butoxyethanol,	5%	Sodium	EDTA)	at	95°C	for	10	min.	The	primary	antibody	anti	human	AR-V7	was	a	rabbit	monoclonal	antibody	(Abcam)	used	at	the	dilution	1:250	for	1	hour	at	room	temperature.	The	primary	antibody	was	replaced	with	rabbit	preimmune	serum	as	a	negative	control	for	non-specific	staining.	Sections	were	finally	counterstained	with	haematoxilyn	and	mounted.	 The	 stained	 sections	 were	 observed	 with	 a	 light	 microscope	 and	 positivity	 was	determined	by	cell	staining.		
Evaluation	of	antigen	positivity	Antigen	expression	was	quantified	according	to	the	following	two	parameters:	(1)	the	number	of	 positively	 stained	 cells;	 (2)	 the	 intensity	 of	 the	 staining,	 ranging	 from	 pale	 pink	 to	 dark	orange.	AR-V7	positivity	was	 graded	 as	 follow:	+/-	weak	 to	moderate	 staining	on	 less	 than	
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10%	of	tumor	cells,	+		weak	or	moderate	staining		on	less	than	50%	of		tumor	cells	or	strong	staining	on	less	than	10%	of	tumor	cells,	++	strong	positivity	on	the	majority	of	tumor	cells.		2.	IN-VITRO	ANALYSIS	On	prostate	carcinoma	cell	 lines	we	evaluated	PI3K/	AKT/	mTOR,	Wortmannin	(WTM)	and	RAD001	inhibitors	 in	combination	with	drugs	that	 interfere	with	AR,	Abiraterone	(ABI)	and	Enzalutamide	 (ENZ),	 and	 Docetaxel	 (DTX).	 We	 chose	 different	 concentrations	 and	 the	treatments	were	performed	for	24,	48	and	72	hours.	Survival	was	assessed	with	MTT,	and	cell	death	with	 tripan	blue	staining.	Western	blot	analyses	was	performe	 to	detect	 the	different	compounds	induced	apoptosis.	Finally,	the	ability	of	the	compounds	to	induce	cell	cycle	arrest	was	evaluate	by	Flow	cytometry.		-Cell	lines	LnCaP,	 androgen-sensitive	 human	prostate	 adenocarcinoma	 cells	and	 VCaP,	 human	prostate	adenocarcinoma	with	a	constitutive	expression	of	AR-V7	were	obtaied	from	Istituto	Nazionale	per	 la	 Ricerca	 sul	 Cancro,	 Genoa,	 Italy	 (ICLC).	 LNCaP	 cells	were	 	 grown	 in	 RPMI	 1640	 and	VCaP	 in	 	 DMEM:	 F12,	 1:1,	 supplemented	 with	 10%	 FBS,	 100	 U/mL	 penicillin,	 100	 µg/mL	streptomycin	and	1%	Non-Essential	Amino	Acids.	Cells	were	maintained	 in	 a	 tissue	 culture	incubator	at	37°C,	5%	CO2.		-Cell	viability	assay	Cytotoxicity	was	assessed	by	TB	dye	exclusion	test.	Briefly,	exponentially	growing	cells	were	suspended	in	a	number	density	of	1	x	105	ml-1	in	24-well	microplate.	After	48		h,		control	and	treated	cells		were	washed	in	PBS,	trypsinized	and	harvested,	diluted	(1:1)	in	a	0.4%	TB	stain	solution	and	counted	using	an	optical	microscope	 in	a	Neubauer	chamber.	The	cell	viability	was	determined	and	expressed	as	percentage	compared	to	the	corresponding	control.	The	cell	viability	in	control	samples	was	always	95-98%	of	the	total	number	of	cells.	Reported	values	result	from	the	average	of	at	least	three	independent	experiments.		
Cytotoxicity	assessed	with	Trypan	Blue	PC-3	and	SK-Mel-5	and	-28	were	plated	and,	after	24	hours,	treated	with	derivatives	of	kinesin	inhibitors	at	different	 concentrations	 (from	0.1	μM	 to	100	μM)	and	 for	different	 incubation	times	(24	,	48	and	72	hours).	
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At	the	end	of	the	incubation,	the	cells	were	trypsinized.	Initially,	the	nutritive	material	and	the	cells	washed	with	3-4mL	of	phosphate	buffer	(PBS),	sterile	and	free	of	Ca	+	2	and	Mg	+	2,	were	removed	 in	order	 to	 loosen	 the	calcium-dependent	contacts	between	 the	cells	and	between	these	and	the	plate.	The	PBS	was	also	used	to	remove	residues	of	culture	medium	containing	trypsin	inhibitors;	after	washing,	1ml	of	trypsin	/	EDTA	solution	(EuroClone)	was	added.	At	this	point	the	cells	were	placed	in	an	incubator	for	15	minutes.	Once	 the	adhesion	 loss	of	 the	 cells	was	verified,	under	 the	microscope,	 they	were	 collected	with	PBS	(3-4	ml)	and	their	count	with	Trypan	Blue	(TB),	a	dye	able	to	selectively	color	the	dead	cells.	Then,	20μL	of	the	cell	suspension	and	20μL	of	dye	were	withdrawn;	after	a	slow	and	 repeated	 suspension	 an	 aliquot	 of	 20μL	 was	 taken	 and	 placed	 in	 the	 hemocytometer	count	chamber	(Neubauer	improved	0.100mm).	Under	the	 inverted	microscope	the	relationship	between	 living	cells	(refractories)	and	dead	cells	(colored	in	blue)	was	evaluated.	Each	count	was	performed	at	least	three	times	and	the	average	was	assessed.	Finally,	the	vitality	was	determined	and	expressed	as	a	percentage	with	respect	to	the	growth	of	the	untreated	cells.		
	Figure	3:	Cells	seen	under	a	light	microscope	with	Trypan	Blue	(on	the	left),	Neubauer's	Room	(on	the	right).	
	-Cell	proliferation	assay	MTT	assay	was	performed	to	determine	proliferation	activity.	Cells	(5	x	103)	were	seeded	in	96-well	 flat	 plate	 and	 allowed	 to	 attack	 for	 24	 h.	 Cells	 were	 treated	 with	 Docetaxel,	abiraterone,		ecc	.	After	treatment,	the	cells	were	washed	with	PBS	to	remove	the	compounds	in	excess,	and	 incubated	with	MTT	for	4	h.	The	 formed	formazan	crystals	were	dissolved	 in	100	 μl	 of	 DMSO	 for	 15	min.	 Finally	 the	 absorbance	 at	 the	 test	wavelength	 of	 540	 nm	was	measured	in	a	plate	reader	spectrophotometer	(Labsystem	Multiskan	MS),	using	a	reference	wavelength	of	690	nm.	Cells	 incubated	with	 culture	medium	alone	 represented	 the	 control,	whereas	wells	containing	medium	alone	represented	the	blank.	The	amount	of	surviving	cells	
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was	 expressed	 as	 percentage	 of	 the	 corresponding	 control	 sample,	 obtained	 by	 the	 ratio	between	 the	 two	 measured	 absorbance	 values.	 The	 reported	 results	 are	 obtained	 by	 the	average	of	at	least	three	experiments	performed	with	independent	preparations	of	entrapped	DOX.		
Cytotoxicity	evaluated	with	MTT	The	potential	cytotoxic	effect	of	the	different	K858	derivatives	was	evaluated	on	the	PC-3,	SK-Mel-5	and	-28	cells	in	the	proliferative	phase	by	the	MTT	assay.	
	
Figure	4:	Reduction	reaction	of	MTT	to	formazan	derivative.	
	The	 method	 is	 based	 on	 the	 transformation	 of	 3-	 [4,5-dimetiltiazol-2-yl]	 -2,5-diphenyl	tetrazolium	bromide	(MTT,	Sigma-Aldrich).	This	yellow	tetrazolium	salt	is	reduced	(figure	4),	in	 the	mitochondria	 from	 the	 enzyme	 succinate	 dehydrogenase	 of	 the	 vital	 cells,	 in	 blue	 /	violet	 coloring.	 The	 assay	 is	 to	 solubilize	 the	 crystals	 after	 4	 h	 of	 incubation,	with	100μl	 of	DMSO	and	after	15	 'the	absorbance	 is	measured	at	 a	wavelength	of	540	and	690nm	with	a	micro-plate	reader	Elisa	Reader	(Labsystem	Multiskan	MS,	figure	5).	The	specific	absorbance	is	obtained	by	subtracting	the	non-specific	value	obtained	at	690nm.	Exponentially	growing	cells	 (PC-3,	 SK-Mel-5	 and	 -28)	 were	 seeded	 in	 triplicate	 in	 96-well	 plates	 (Corning,	 Inc.,	Corning,	Ny,	USA)	at	a	density	of	5000	cells	per	well	(optimal	number	that	allows	both	of	not	having	 an	 excessive	 growth	 of	 cells	 in	 the	 control	 well,	 is	 a	 better	 discrimination	 of	 the	pharmacological	action)	and	in	100μl	of	complete	soil.	Subsequently	incubated	for	24	hours	at	37	°	C	at	5%	of	CO2,	to	allow	the	adhesion	of	the	cells	to	the	plate.After	24	hours,	the	diluted	kinesin	inhibitors	were	added	to	each	well	and	the	cells	incubated	for	the	expected	treatment	times.	
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On	the	day	of	the	assay	20μl	of	tetrazolium	salt	were	added	to	have	a	concentration	of	0.5mg	/	ml	per	well	and	finally	the	precipitated	formazan	crystals	were	solubilized	in	DMSO	and	the	absorbance	measured	with	an	Elisa	micro	plate	Reader.	The	percentage	of	proliferating	cells	was	therefore	obtained	from	the	ratio:	𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑤𝑖𝑡ℎ 𝑡ℎ𝑒 𝑑𝑟𝑢𝑔𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑐𝑒𝑙𝑙 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑚𝑒𝑑𝑖𝑐𝑎𝑡𝑖𝑜𝑛 	To	all	the	values	the	absorbance	obtained	in	the	white	was	subtracted	(reading	in	triplicate	of	wells	without	 cells	with	only	 the	 culture	medium).	The	 result	 obtained	 is	 the	 average	of	 at	least	three	readings.	
	
Figure.5:	Elisa	reader	-Western	blot	After	 treatment	 of	 the	 LnCaP	 and	 VCaP	 cells	 with	 the	 different	 compounds,	 these	 were	washed	with	PBS,	collected	and	lysed	in	ice	with	125μl	of	buffer,	containing	1%	of	Triton	X-100,	0.2%	Nonidet	P-40	with	2ml	of	EDTA,	2mg	/	ml	sodium	ortovanadate	and	1x	protease	inhibitor	(Roche	Applied	Sciences).	The	proteins	were	separated	with	10%	SDS-PAGE	buffer	(SodiumDodecylSulphate	 -	 PolyAcrylamide	 Gel	 Electrophoresis)	 and	 subsequently	transferred	to	PVDF	(polyvinylidenefluoride)	membranes.	For	immunoblotting,	the	following	primary	antibodies	were	used:	anti-Parp-1	mouse	(dilution	1:	500)	 (Santa	Cruz	Biotechnology);	 anti-Actin	mouse	 (1:	1000	dilution)	 (Sigma	Aldrich)	 as	internal	control.	Subsequently,	 they	were	 incubated	 for	1	hour	at	room	temperature,	with	a	second	anti-mouse	or	anti-rabbit	antibody	conjugated	with	horseradish	peroxidase	(dilution	1:	5000)	(Sigma-Aldrich).	The	chemiluminescent	(ECL)	analysis	with	the	addition	of	enhanced	chemiluminescence	 (Super	Signal	West	Pico	Chemiluminescent	Substrate,	ThermoScientific)	
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was	visualized	using	Kodak	X-Omat	plates.	The	densitometry	of	 the	bands	 is	obtained	using	the	software	Image	J.		
Western	blot	Cell	lysates	were	obtained	scraping	the	cells	in	lysis	buffer	containing:	1%	Triton,	0.1	%	SDS,	150	mM	NaCl,	 50	mM	TRIS-HCl	 pH	 7.4,	 2	mM	EDTA	plus	 protease	 inhibitor	 cocktail	 tablet	(Roche	Applied	Sciences)	for	30	min	at	4	°C,	then	centrifuged	at	16,000	x	g	for	15	min	at	4	°C.	Protein	concentration	was	evaluated	by	the	Protein	Concentration	Assay	(Bio-Rad).	Samples	of	lysate	(50-100	µg)	were	separated	by	molecular	weight	on	10%	or	12%	SDS-PAGE	(under	reducing	condition)	and	 then	 transferred	 into	a	nitrocellulose	membrane.	Membranes	were	blocked	for	1	hr	at	room	temperature	(RT)	 in	5%	non-fat	dry	milk	and	then	incubated	with	primary	 antibody,	 washed	 in	 TRIS-buffered	 saline	 added	 with	 0.1%	 Tween	 20	 and	 then	incubated	 with	 horseradish	 peroxidase	 conjugated	 anti-mouse	 or	 anti-rabbit	 antibodies	(1:5000	 diluted,	 Sigma-Aldrich).	 The	 filters	 were	 then	 developed	 by	 enhanced	chemiluminescence	(Super	Signal	West	Pico	Chemiluminescent	Substrate,	Thermo	Scientific)	using	Kodak	X-Omat	films.	The	densitometry	quantitation	of	the	bands	was	performed	using	Image	 J	 software.	 The	 primary	 antibodies	 were	 the	 following:	 mouse	 anti	 Parp1	 (1:500	diluted,	Santa	Cruz	Biotechnology);	mouse	anti-actin	(1:1000	diluted,	Sigma	Aldrich).			-Flow	cytometry	analysis	Flow	cytometry	was	used	to	detect	quantitatively	the	distribution	of	cell	cycle.	After	48	h	of	incubation	with	different	compounds,	both	adherent	and	floating	cells	were	collected	in	ice-cold	 phosphate	 buffer	 (PBS)	 and	 then	 1.0x106	 were	 fixed	 in	 2	 mL	 ethanol	 70%,	 and	 then	incubated	1	h	at	4	C.	Cellular	pellet	was	dissolved	in	0.2	mL	of	50	µg/mL	propidium	iodide	and	100	µg	/mL	RNase	A	in	PBS.	The	stained	cells	were	incubated	at	room	temperature	for	30	min	in	the	dark.	The	DNA	content	of	the	cells	was	analyzed	by	FACS	Canto	II	flow	cytometry	using	the	FACS	Diva	analysis	program	in	order	to	detect	the	distribution	of	subpopulation	through	the	cell	cycle.			
Cytofluorimetric	analysis	(FACS)	Cytofluorimetric	analysis	was	used	to	quantitatively	determine	the	distribution	of	cells	in	the	various	phases	of	the	cell	cycle	and	apoptosis.	Ploidy	levels	were	evaluated	after	staining	with	propidium	iodide.	
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The	 propidium	 iodide	 (PI)	 is	 a	 synthetic	 dye	 characterized	 by	 a	 low	 fluorescence	 (red-orange),	able	to	bind	in	a	non-specific	way	the	nucleic	acids,	both	the	DNA	and	the	RNA,	with	double	 helix.	 Once	 intercalated	 between	 the	 base	 pairs,	 the	 PI	 greatly	 increases	 the	fluorescence	quantum	efficiency,	thus	favoring	the	determination	of	the	2N	and	4N	peaks.	With	this	method,	it	is	also	possible	to	evaluate	cell	apoptosis,	exploiting	the	internucleosomal	cut	of	DNA	in	the	apoptotic	cell.	The	 PI,	 binds	 stoichiometrically	 to	 the	 double	 helix	 of	 DNA	 provides	 information	 on	 the	amount	 of	 deoxyribonucleic	 acid	 contained	 in	 the	 cells,	 depending	 on	 the	 intensity	 of	fluorescence	(the	higher	the	content	of	DNA	the	greater	the	fluorescence,	λ	488nm).	It	is	known	that	the	DNA	content	varies	according	to	the	phase	of	the	cycle	in	which	a	cell	is	located.	In	particular,	phase	G2	and	mitosis	have	a	double	amount	of	DNA	with	respect	to	the	G1	phase;	while	during	the	DNA	synthesis	phase,	the	cell	has	a	quantity	of	DNA	intermediate	between	the	content	in	G1	and	G2.	Apoptotic	 cells,	 on	 the	 other	 hand,	 have	 a	 reduced	 colorability	 of	DNA	 compared	 to	 live	 or	dead	cells	by	necrosis;	in	fact,	once	they	are	resuspended	in	an	appropriate	buffer,	they	lose	the	 small	 fragments	 of	 DNA	 and	 it	 is	 possible	 to	 observe	 in	 them	 a	 reduction	 of	 the	fluorescence	 of	 the	 PI	 (correlated	 to	 the	 decrease	 of	 the	 DNA	 content).	 In	 this	 way	 it	 is	possible	 to	 evaluate	 the	 percentage	 of	 apoptotic	 cells	 that	 are	 positioned	 in	 the	 so-called	hypodiploid	peak,	with	 lower	 colorability	 compared	 to	 cells	 in	G1	 (marker	of	 apoptotic	 cell	death)	and,	in	addition	to	this,	the	percentage	of	cells	in	the	various	phases	of	the	cycle	mobile	phone:	G0	/	G1,	S	and	G2	/	M.	Twenty-four	 hours	 after	 seeding	 the	 cells,	 treatments	 with	 5μM	 of	 some	 derivatives	 are	carried	out	and	after	an	incubation	of	24	and	96	hours,	the	cells	are	trypsinized,	washed	with	cold	PBS,	resuspended	at	a	concentration	of	1x106,	fixed	with	ethanol	at	70%	and	incubate	1	hour	at	4	°	C.	The	cell	pellet	is	dissolved	in	0.5ml	of	a	solution	containing	propidium	iodide	(5μg	/	ml)	and	RNase	 (1mg	 /	ml)	 in	 PBS.	 The	 cells	 so	 colored	 are	 incubated	 at	 room	 temperature	 for	 30	minutes	in	the	dark.	The	DNA	contained	in	the	treated	cells	and	controls	was	analyzed	at	the	FACS	Canto	II	using	the	FACS	DIVA	program	(Fugure	6).	
	
Propidium	Iodide 
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								Figure	6:	BD	FACSCanto	clinical	software	and	BD	FACSDiva™	software			3-STATISTICAL	ANALYSIS	Ex-vivo	experiments	were	performed	at	least	three	times	and	the	statistical	significance	was	evaluated	by	chi	square	test.	Significance	level	was	considered	at	0.05. 	RESULTS	1.	EX	VIVO	AR-V7	EXPRESSION		A	retrospective	study	was	performed	 in	order	to	evaluate	the	cellular	expression	of	human	androgen	 receptor	 variant	 AR-V7	 in	 the	 tumor	 tissues	 from	 72	 PCa	 patients	 selected	 and	divided	into	four	groups:	22	patients	with	high	risk	and	disease	progression	(A1),	22		patients	with	high	risk	and	no	progression	(A0),	14	intermediate	risk	and	no	progression	(I0),	14	low	risk	and	no	progression	(B0).	All	 14	 patients	 B0	 resulted	 totally	 negative	 for	 AR-V7	 staining	 of	 tumor	 cells;	 13	 over	 14	(92.8%)	 patients	 I0	 resulted	 totally	 negative	 and	 only	 one	 patient	 (7.14%)	 showed	 1%	 of	tumor	 cells	with	 nuclear	 staining	 for	 AR-V7.	 Among	 the	 22	 patients	 A0,	 14	 (63.63%)	were	totally	negative	and	8	 (36.36%)	showed	only	1-2%	of	 tumor	 cells	with	nuclear	 staining	 for	AR-V7.	 	All	 22	 (100%)	patients	A1	 showed	AR-V7	nuclear	 staining	 in	 a	 variable	number	of	tumor	cells	ranging	 from	2	to	10%	of	positive	cells	(Figure7).	We	calculated	the	correlation	between	the	positive	nucelar	staining	of	AR-V7	and	the	clinical	stage	or	progression	using	the	chi-square	 test	 whose	 results	 were	 4,38499E-07	 and	 	 9,60943E-11,	 respectively.	 We	compared	 our	 data	 with	 the	 chi-square	 distribution	 table	 and	 the	 hypothesis	 of	 the	correlation	must	be	accepted.			
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	Figure	7:	Immunoperoxidase	staining	with	anti	AR-V7		on	prostate	cancer	at	different	stages.	High	risk	and	progression	cancer	(A-B)	showing	many	tumor	cells	with	strong	positive	nuclear	staining.	High	risk	and	no	progession	cancer	(C)	showing	few	cells	with	low	nuclear	positive	 staining.	 Intermediate	 risk	 and	 no	 progression	 cancer	 (D)	with	 negative	 staining	 for	 all	 cells.	 Low	 risk	 cancer	 (E)	with	 negative	staining	for	all	cells.	The	magnification	is	20X	for	panels	A,	C,	D,	E	and	40X	for	panel	B.				2.	IN-VITRO	ANALYSIS	We	 analyzed	 the	 sensitivity	 of	 PCa	 cell	 lines	 to	 single	 agent	 treatment	 to	 determinate	 the	dose-	response	curves		by	trypan	blue	exclusion	assay,	similar	results	were	obtained	by	MTT	(3-(4,5-dimetiltiazol-2-il)-2,5-difeniltetrazole	assay)	(figure	8).		
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Figure.	8:	Determination	of	single	compound	on	cell	line.	The	first	results	showed	that	DTX	has	a	greater	ability	to	inhibit	cell	growth	of	both	cell	lines:	after	treatment	with	2,5nM	only	14%	and	30%	respectively	LnCaP	and	VCap	cells	are	live.	Treatment	with	ABI	reduces	the	growth	of	LnCaP	by	only	40%	and	that	of	VCaP	by	20%,	while	ENZA	reduces	by	55%	the	LnCaP	(survive	45%)	and	by	30%	(survive	70%)	the	VCap	(TB	data).		A	 combination	 of	 the	 different	 compounds	 can	 highlight	 the	 reciprocal	 effect	 on	 the	 of	 the	different	 cell	 lines.	 In	 this	 context	 	 LnCaP	 and	 VCaP	 cell	 lines	 were	 treated	 with	 WTM	 (a	representative	 inhibitor	 of	 PI3K)	 and	 RAD001	 (an	 inhibitor	 of	 mammalian	 target	 of	rapamycin	 (mTOR))	combined	 to	DTX	or	drugs	 that	act	by	 inhibiting	AR	pathway,	ENZ	(AR	signaling	 inhibitor)	 or	 Abi	 (Cyp	 450	 17A1	 inhibitor).	 The	 proliferative	 effects	 were	determined	by	MTT	(Figure	9).			It	 is	highlighted	that	DTX	is	the	drug	that	mainly	interacts	with	cellular	growth,	 less	evident	by	 treatment	with	Abi	 and	 ENZ.	 Combined	 treatments	with	DTX	 further	 decreased	 cellular	proliferation.	The	treatments	on	AR	pathway	combined	with	PI3K/mTOR	inhibitors	synergize	by	 decreasing	 growth.	 In	 our	 experiments	 on	 LnCaP	 cell	 line,	 the	 strongest	 synergism	was	observed	 with	 ENZ+RAD,	 followed	 by	 Abi+WTM.	 Similar	 results	 were	 observed	 in	experiments	on	VCaP.						
	Figure	9:	Combination	effect	of	therapies	targeting	the	AR-	and	PI3K/mTOR	signaling	pathway.	In	LNCaP	treatment	with	DTX	(2,5nM)	+	WTMN	(100nM)	(survival	7.7%)	showed	in	MTT	assay	a	decrease	by	1.81	times	the	growth	of	cells	compared	to	those	treated	with	1nM	DTX	(14%);	a	 further	1.5%	treatment	with	1nM	DTX	+	100nm	RAD001	(survival	9.5%,	14%	1nM	DTX),	 therefore	treatment	with	a	 lower	concentration	of	DTX	and	an	integration	at	different	points	of	PI3/	mTOR	had	as	a	result	of	a	further	reduction	in	LnCaP	growth.	Treatment	of	LnCaP	with	10	μM	ABI,	5μM	ABI	+	100	mM	WTMN,	5μM	ABI	+	100nM	RAD001,	showed	respectively:	60%,	35%,	41%	of	proliferating	cells.	Treatment	of	LnCaP	with	10	μM	of	ENZA,	5	μM	ENZA	+	100	mM	WTMN,	5	μM	ENZA	+	100nM	RAD001,	5	μM	ENZA	showed	respectively:	45%,	
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38%	and	25%	of	proliferating	cells	.	The	percentage	of	LnCaP	lives	after	treatment	with:	100nM	WTMN,	100nM	RAD001	was	78%,	and	70%,	respectively.		It	 is	highlighted	that	DTX	is	the	drug	that	mainly	interacts	with	cellular	growth,	 less	evident	by	 treatment	with	Abi	 and	 ENZ.	 Combined	 treatments	with	DTX	 further	 decreased	 cellular	proliferation.	The	treatments	on	AR	pathway	combined	with	PI3K/mTOR	inhibitors	synergize	by	 decreasing	 growth.	 In	 our	 experiments	 on	 LnCaP	 cell	 line,	 the	 strongest	 synergism	was	observed	 with	 ENZ+RAD,	 followed	 by	 Abi+WTM.	 Similar	 results	 were	 observed	 in	experiments	on	VCaP.	To	 establish	 the	 causal	 relationship	 between	 cell	 growth	 arrest	 and	 death,	we	 investigated	whether	 the	 different	 compounds,	 alone	 or	 combined,	 induced	 apoptosis	 by	 analyzing	 Poly	(ADP-ribose)	polymerase	(PARP)	1	cleavage	carrying	out	a	western	blot	(Figure10).		
					Figure	10:	Effects	of	DTX,	AR	and	PI3K/mTOR	inhibitors	in	induction	of		apoptosis.	Western	blot	of	LnCaP	A)and	VCaP	B)cell	lines	 untreated	 (Ct)	 and	 treated	 for	 24	 hr	 with	 different	 combination	 for	 PARP1.	 Cleaved	 PARP	 detects	 the	 induction	 of	apoptosis.		The	cleavage	of	PARP1	is	always	evident	 in	cells	 treated	with	DTX,	specially	combined	with	WTM.	But	while	PARP	cleaved	is	little	or	nothing	detected	in	cells	treated	both	Abi	or	ENZ,	it	becomes	clearly	detected	in	combined	treated	cells.	Targenting	 both	 AR	 and	 PI3K/mTOR	 signaling	 pathway	 resulted	 in	 an	 inhibition	 of	 cells	growth	and	an	induction	of	apoptosis	in	LnCaP	as	well	as	in	VCaP	that	presents	AR-V7.	
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To	study	cell	cycle	affected	by	AR	or	PI3K/mTor	pathway	inhibitors	as	well	as	DTX,	cells	were	treated	with	 the	different	compounds,	alone	or	combined,	 for	48	hrs,	and	DNA	content	was	evaluated	using	flow	cytometry	(Figure	11).					
		Figure	 11:	 Targeting	 AR	 and	 PI3K/mTOR	 induces	 cell	 cycle	 arrest	 in	 prostate	 cancer	 cell	 lines.	 Distribution	 of	 cell	 cycle	 phase	 was	determined	by	flow	cytometry	in	LnCaP	A)	and	in	VCaP	B).	The	treatment	with	DTX	increases	G2/M	arrest,	increased	by	adding	WTM.	The	combination	with	WTMN	increases	G2/M	and	decreases	S	phase	population	in	all	samples.	AR	inhibitors	increase	Go/G1	and	reduce	S	phase	in	LnCaP	and	VCaP.			It	 is	 already	 known	 that	 taxane	 treatments	 as	 DTX,	 distruptioning	 microtubuli	 function,	induced	an	increased	percentage	of	cells	in	G2/M	and	a	reduction	of	S	phase	population.	The	adding	of	WTM	also	induced	G2/M	arrest	in	all	the	samples	with	a	reduction	of	S	phase.	The	treatment	DTX+WTM	makes	 it	 strongest	 in	both	cell	 lines.	AR	pathway	 inhibitors	 increased	G0/G1	and	decreased	S	Phase	population.	
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These	effects	contribute	to	inhibition	of	cell	growth	and	induction	of	apoptosis	in	cells	treated	with	DTX	as	well	inhibitors	of	AR	and	PI3K/mTOR	signaling	pathway.				DISCUSSION	Patients	with	the	metastatic	PCa	often	develop	a	progression	towards	the	metastatic	form	of	the	disease,	known	as	castration-resistant	prostate	cancer	(CRPC).	For	this	group	of	patients	the	 traditional	 treatment	based	on	 taxanes,	 as	well	 as	 the	 treatment	with	abiraterone	 (Abi)	and	enzalutamide	(ENZ),	may	have	limited	effectiveness	resulting	in	a	poor	survival	rates,	the	median	duration	of	response	is	less	than	one	year	(48).	CRPC	can	results	from	several	molecular	mechanisms:	gain	of	function	of	androgen	receptor	(AR)	 and	 activation	 of	 PI3K/mTOR	 signaling	 pathway	 also	 through	 loss	 of	 PTEN	 often	correlates	with	this	disease	(74).	Data	from	clinical	trials	have	shown	a	moderate	response	in	patient	 treated	 with	 a	 single	 agent	 probably	 due	 to	 the	 complex	 compensatory	 crosstalk	between	 the	AR	and	PI3K	pathways	(75,76).	Thus	a	combined	 treatment	 targeting	both	 the	pathways	could	be	an	alternative	treatment	(76).		Resistance	 to	Abi	and	ENZ	 is	often	correlate	 to	constitutively	active	AR	splice	variants	 (AR-Vs),	of	which	AR	variant-7	(AR-V7)	is	the	most	well	studied	(48).	In	 the	 first	 part	 of	 the	 thesis	we	 analyzed	 the	 presence	 of	 AR-V7	 in	 sample	 obtained	 from	patients	submitted	to	radical	prostatectomies	with	different	stage	disease	and	we	observed	a	strong	AR-V7	nuclear	positivity	only	in	patients	with	high	risk	and	progression	cancer.	In	both	cases	the	chi-square	test	showed	that	there	is	a	correlation	between	the	two	variables	taken	into	consideration,	but	given	that	the	value	obtained	by	the	receptor-progression	correlation	is	more	negative	than	the	value	obtained	by	the	receptor-risk	correlation,	it	can	be	stated	that	the	correlation	receptor-progression	is	statistically	"stronger"	than	the	receptor-risk.	In	the	second	part	of	the	thesis	we	also	analyzed	the	effects	of	docetaxel	(DTX)	or	compounds	that	target	AR	or	PI3K/mTOR	in	combination	each	others	on	AR	positive	cell	lines,	LnCaP	and	VCaP,	 VCaP	 also	 shows	 AR-V7	 spliced	 variant.	 LnCaP	 are	 	 Phosphate	 and	 tensin	 homolog	(PTEN)	negative	prostate	cells.		As	 expected	 we	 found	 that	 Docetaxel	 (DTX)	 induced	 proliferative	 reduction	 with	 a	 G2/M	accumulation	of	cells	and	a	reduction	of	S	phase	population,		activation	of	apoptosis	can	cause	the	 death	 in	 both	 treated	 cell	 lines.	 This	 suggest	 that	 the	 addition	 PI3K/mTOR	 inhibitor	 to	classical	 therapies	 can	 enhance	 therapeutic	 efficacy,	 mostly	 wortmannin.	 It	 is	 konwn	 that	
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WTM	 shows	 substantial	 in	 vivo	 toxicity	 and	 thus	 is	 unsuitable	 for	 systemic	 therapeutic	applications	but	several	compounds	that	bind	to	and	inactivate	 	PI3K	 	are	 in	preclinical	and	clinical	trials.	Enzalutamide	 (ENZ),	 AR	 signaling	 inhibitor	 or	 Cyp	 450	 17A1	 inhibitor	 abiraterone	 (Abi)	decrease	both	cells	growth,	more	evident	in	LnCap	compared	to	VCap.	ENZ	and	Abi	induce	G1	arrest	 cycle.	 Analyzing	 the	 effects	 	 of	 combining	 treatment	 of	 AR	 inhibitor	 in	 AR	 positive	conditions,	LnCaP	and	VCaP	cells,	with	PI3K/mTOR	inhibitors	we	can	detect	that	the	adding	of	RAD001	 is	more	effective	 in	 inducing	apoptosis	and	G1	arrest	even	 though	WTM	treatment	induces	a	more	cell	growth	inhibition.		These	results	suggest	that	targeting	PI3K/mTOR	combinig	with	the	other	drugs	could	be	an	useful	clinical	approach	in	hormone	sensitive	PC	and	CRPC	but	these	experimental	are	need	to	be	supported	by	clinical	trials.																								
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